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Abstract 
In mammali an ce ll s. the loss or down-regulati on of tumour-suppresso r genes and/o r the 
mutation or ove rexpress ion of pro to-oncogenes. whose products promote unregulated 
pro liferati on in ce ll s. ch aracte ri se th e process of mali gnant transformati on. This 
generates mitogenic signals th at promote abnorm al ce ll gro wth resulting in tumour 
progress ion. Topoisomerase Ila (topo Il a) an enzyme present in e levated 
concentra ti ons in hi ghly pro liferating ce ll s due to the requirement fo r un twisting and 
unknottin g of the D A \vhich is essenti al fo r replicati on. Because of thi s requirement. a 
number of anti-cancer dru gs have been de igned \\'ith topo Il a as their primary targe t. 
The effecti ve ness of these drugs however is limited by the deve lopment of res istance. 
One factor linked to drug res istance is the down-regulati on oftopo Ila at th e transcription 
leve l. Expre sion of topo Il a ap pear to be regulated th rough vari ous transc ription 
fac tor \\ ith member of th e Sp I fam il y havi ng a majo r contribut ion. 
Prev ious work has shown down regulation o f topo Ila can occur at the leve l of 
transc ription. Nucleotide sequenc in g of the topo Ila pro moter in dru g-res istant ce ll lines 
has not revea led any mutations thus fa r. Three kn own pro teins and one unch arac terised 
protein are capab le of interacting \\ ith the proxima l topo Il a promote r reg ion. The 
uncharac teri sed prote in may ac t as a co-ac ti vator or a co-re pressor depend ing on the 
co mplement of tra nsc ript ion fac tors assoc iated \Vith the D A in thi s reg ion. Because 
drug res i tant ce ll lines showed modul ated exp ression of th ese tran cript io n fac tors. it is 
important to identi fy the unknown pro te in and charac teri se it s ro le in regulatin g topo Il a 
express ion. 
This research aimed to identi fy the minimal bindin g s ite and D A elements required fo r 
the uncharacteri sed prote in to bind , as we ll as introduce mutations into thi s proximal 
reg ion and examine their functi onal significance . The results of thi s stud y could provide 
insights into the molecular mechani sms responsible for the deve lopment of dru g 
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